

Please amend the subject application as follows.

In the Specification:

Please delete the paragraph at page 3, lines 1-6, and replace it with the following rewritten paragraph:

-- Peach et al., (J. Exp. Med. (1994) 180:2049-2058) identified regions in the CTLA4 extracellular domain which are important for strong binding to CD80. Specifically, a hexapeptide motif (MYPPPY) (SEQ ID NO:9) in the complementarity determining region 3 (CDR3)-like region was identified as fully conserved in all CD28 and CTLA4 family members. Alanine scanning mutagenesis through the MYPPPY motif in CTLA4 and at selected residues in CD28Ig reduced or abolished binding to CD80. --

REMARKS

The October 11, 2002 Notice states that the subject patent application fails to comply with the Sequence Rules under 37 C.F.R. §1.821-1.825. In particular, the Notice states that a paper copy and a computer-readable form of the amino acid sequence "MYPPPY" is missing. A copy of Part 2 of the Notice is submitted herein as Exhibit 1.

In response, Applicants amend the specification herein to include and a sequence listing indicator number (e.g., SEQ ID NO:9) for the "MYPPPY" amino acid sequence. This Amendment now places the subject application in compliance with 37 C.F.R. §1.821-1.825. Further, the changes are supported by the originally-filed specification and do not contain new matter.

A page entitled "Version with Markings to Show Changes in the Specification" is attached hereto to show the changes made to the specification.

Applicant: Robert J. Peach, et al.
U.S. Serial No.: 09/865,321
Filed: May 23, 2001
Page: 3

A page entitled "Version with Markings to Show Changes in the Specification" is attached hereto to show the changes made to the specification.

Applicants also submit herein a paper copy (Exhibit 2) and computer-readable form of the Sequence Listing. Applicants submit herein a Declaration under 37 C.F.R. §1.821(f) (Exhibit 3) attesting that the content of the paper copy and computer-readable form are the same. The paper copy and computer-readable form of the Sequence Listing contain no new matter and entry of the Sequence Listing is respectfully requested.

No fee is deemed necessary for the filing of this Preliminary Amendment. However if any fee is necessary, the Patent Office is authorized to charge any additional fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Roberta D. German
Registration No. 43,902
Patent Practitioners for Applicants
Mandel & Adriano
55 So. Lake Ave., Suite #710
Pasadena, California 91101
(626) 395-7801
Customer #26,941

Applicant: Robert J. Peach, et al.
U.S. Serial No.: 09/865,321
Filed: May 23, 2001
Page: 4

VERSION WITH MARKINGS
TO SHOW CHANGES IN THE SPECIFICATION

Please amend the paragraph at page 3, lines 1-6, to read as follows:

-- Peach et al., (J. Exp. Med. (1994) 180:2049-2058) identified regions in the CTLA4 extracellular domain which are important for strong binding to CD80. Specifically, a hexapeptide motif (MYPPPY) (SEQ ID NO:9) in the complementarity determining region 3 (CDR3)-like region was identified as fully conserved in all CD28 and CTLA4 family members. Alanine scanning mutagenesis through the MYPPPY motif in CTLA4 and at selected residues in CD28Ig reduced or abolished binding to CD80. --